Prosecution Insights
Last updated: November 12, 2026
Application No. 18/899,597

METHODS OF TREATING INTERSTITIAL LUNG DISEASES AND OTHER FIBROTIC-MEDIATED PULMONARY DISEASES AND DISORDERS WITH DEUPIRFENIDONE

Non-Final OA §103
Filed
Sep 27, 2024
Priority
Mar 31, 2022 — provisional 63/326,132 +12 more
Examiner
SAEED, KAMAL A
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Puretech Lyt 100 Inc.
OA Round
1 (Non-Final)
84%
Grant Probability
Favorable
1-2
OA Rounds
94%
With Interview

Examiner Intelligence

Grants 84% — above average
84%
Career Allowance Rate
1023 granted / 1220 resolved
+23.9% vs TC avg
Moderate +10% lift
Without
With
+9.8%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
36 currently pending
Career history
1243
Total Applications
across all art units

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-7 are currently pending in this Application. Priority CONTINUING DATA This application is a CON of PCT/US2023/017213 03/31/2023 PCT/US2023/017213 has PRO 63/432,208 12/13/2022 PCT/US2023/017213 has PRO 63/431,530 12/09/2022 PCT/US2023/017213 has PRO 63/403,481 09/02/2022 PCT/US2023/017213 has PRO 63/374,362 09/01/2022 PCT/US2023/017213 has PRO 63/356,653 06/29/2022 PCT/US2023/017213 has PRO 63/352,107 06/14/2022 PCT/US2023/017213 has PRO 63/341,828 05/13/2022 PCT/US2023/017213 has PRO 63/341,281 05/12/2022 PCT/US2023/017213 has PRO 63/341,279 05/12/2022 PCT/US2023/017213 has PRO 63/341,269 05/12/2022 PCT/US2023/017213 has PRO 63/326,129 03/31/2022 PCT/US2023/017213 has PRO 63/326,132 03/31/2022 Information Disclosure Statement Applicants’ Information Disclosure Statement, filed on September 27, 2024, has been considered. Please refer to Applicant’s copies of the 1449 submitted herewith. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim 1-7 are rejected under 35 U.S.C. 103 as being unpatentable over WO 2019/199864 A1 to Shah. The instant claims are drawn to a method of treating a subject having a fibrotic-mediated pulmonary disease or disorder comprising administering to the subject in need thereof a total daily dose from about 825 to about 2475 mg of a therapeutically effective amount of a deuterium-enriched pirfenidone having the structure shown below: PNG media_image1.png 92 157 media_image1.png Greyscale (LYT-100). Dependent claims 2-7 further limit the total daily doses administered to the subject. Determining the scope and contents of the prior art. (See MPEP § 2141.01) Shah teaches administration of a therapeutically effective amount of a N-aryl pyridinone for treating fibrotic-and/or collagen-mediated disorders (Abstract; para [0005-0007]). Shah particularly teaches administering the deuterium-enriched compound of the instant claims for treating pulmonary fibrosis (para [0011-0022], [0058-0060]). Shah teaches the compound can be administered in the form of one, two, three, four, five, six, or more doses at appropriate times throughout the day, and that each dose ranges from about 0.1-1000 mg (para [00245]). Oral administration is taught (para [0029], [00143]). As such, one of ordinary skill in the art would have found it prima facie obvious to have orally administered deuterium enriched pirfenidone to treat pulmonary fibrosis at a dose of 500 mg. provided twice daily for a total dose of 1000 mg.; a dose of 750 mg. provided twice daily for a total dose of 1500 mg; a dose of 500 mg. provided three times daily for a total dose of 1500 mg; and a dose of 750 mg. provided three times daily for a total dose of 2250 mg., as recited in claims 82-85 respectively, since these doses are included within the dosage range taught by Shah, and Shah further teaches each dose can be administered up to six or more times per day. Ascertainment of the differences between the prior art and the claims. (See MPEP § 2141.02) Shah does not specifically recite the total daily dose from about 825 to about 2475 mg. Finding of prima facie obviousness --- rationale and motivation (See MPEP § 2142-2143) The Supreme Court in KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 415-421, 82 USPQ2d 1385, 1395-97 (2007) identified a number of rationales to support a conclusion of obviousness which are consistent with the proper "functional approach" to the determination of obviousness as laid down in Graham. See MPEP 2143. Examples of rationales that may support a conclusion of obviousness include: (A) Combining prior art elements according to known methods to yield predictable results; (B) Simple substitution of one known element for another to obtain predictable results; (C) Use of known technique to improve similar devices (methods, or products) in the same way; (D) Applying a known technique to a known device (method, or product) ready for improvement to yield predictable results; (E) "Obvious to try" — choosing from a finite number of identified, predictable solutions, with a reasonable expectation of success; (F) Known work in one field of endeavor may prompt variations of it for use in either the same field or a different one based on design incentives or other market forces if the variations are predictable to one of ordinary skill in the art; (G) Some teaching, suggestion, or motivation in the prior art that would have led one of ordinary skill to modify the prior art reference or to combine prior art reference teachings to arrive at the claimed invention. Note that the list of rationales provided is not intended to be an all-inclusive list. Other rationales to support a conclusion of obviousness may be relied upon by Office personnel. Here one or more of rationales (C) and (G) apply. It would have been prima facie obvious for one of ordinary skill in the art to, one of ordinary skill in the art would have found it prima facie obvious to have orally administered deuterium enriched pirfenidone to treat pulmonary fibrosis at a range of doses that are covered by the instant claims. Since shah teach the dose of 500 mg. provided twice daily for a total dose of 1000 mg.; a dose of 750 mg. provided twice daily for a total dose of 1500 mg; a dose of 500 mg. provided three times daily for a total dose of 1500 mg; and a dose of 750 mg. provided three times daily for a total dose of 2250 mg., and these doses fall within the dosage range of the instant claims. Therefore, it would have been obvious to one of ordinary skill in the art to adjust the relative dosage and length of the treatment during routine optimization to find the therapeutically effective dosage and schedule. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). See MPEP 2144.05,II.A. A reference is good not only for what it teaches by direct anticipation but also for what one of ordinary skill in the art might reasonably infer from the teachings. (In re Opprecht 12 USPQ 2d 1235, 1236 (Fed Cir. 1989); In re Bode 193 USPQ 12 (CCPA) 1976). In light of the foregoing discussion, the Examiner concludes that the subject matter defined by the instant claims would have been obvious within the meaning of 35 USC 103(a). From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary. Telephone Inquiry Any inquiry concerning this communication or earlier communications from the examiner should be directed to KAMAL A SAEED whose telephone number is (571) 272-0705. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam C Milligan can be reached at (571)270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000 /Kamal A Saeed/ Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Sep 27, 2024
Application Filed
Oct 29, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790322
POLYMORPHS OF (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE
4y 10m to grant Granted Nov 10, 2026
Patent 12788752
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING TUMOR, AND USE THEREOF
2y 9m to grant Granted Nov 10, 2026
Patent 12790291
INDUSTRIAL PROCESS FOR THE PREPARATION OF HEXANOIC ACID, 6-(NITROOXY)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ETHYLAMINO)-7-OXO-2-HEPTEN-1-YL]-3,5-DIHYDROXYCYCLOPENTYL]-1-(2-PHENYLETHYL)-2-PROPEN-1-YL ESTER AND HIGH PURE PRODUCT
3y 4m to grant Granted Nov 10, 2026
Patent 12790365
SALTS AND CRYSTALLINE FORMS OF (3E) 3-[O-[(PHOSPHONOOXY)METHYL]OXIME]-PREGN-4-ENE-3,20-DIONE AND RELATED USES
3y 0m to grant Granted Nov 10, 2026
Patent 12790344
10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1 ',2':4,5]pyrazino[1,2-B]pyridazine-3,5-dione Derivatives and Related Compounds as Inhibitors of the Orthomyxovirus Replication for Treating Influenza
2y 4m to grant Granted Nov 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
84%
Grant Probability
94%
With Interview (+9.8%)
Low
PTA Risk
Based on 1220 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month